" class="no-js "lang="en-US"> Andrew Bulpin - Medtech Alert
Thursday, July 31, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Andrew Bulpin

Andrew Bulpin

About Andrew Bulpin

Head of Process Solutions, one of the largest and fastest-growing divisions of MilliporeSigma that helps customers develop, make, purify, formulate and assure the quality of their life-enhancing and life-saving drugs

Oversees strategy, product management, marketing, research, development, contract manufacturing and testing services

More than 30 years’ experience with background in strategy, marketing and sales

Approachable leader, courageous competitor and continuous learner

Related Story

Industry News

 MilliporeSigma Announces Acquisition of MAST® Platform from Lonza

MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities

April 6 2022

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, […]